ClinicalTrials.gg
CompletedNCT03185013REVEAL 1Updated Jul 27, 2023Results posted

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

A Phase 3 interventional study of VGX-3100 and Placebo in Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion and HSIL, sponsored by Inovio Pharmaceuticals. Completed at 60 sites in 19 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Inovio Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 109 studies in Uterine Cervical Dysplasia with a site in United States — 10 open to participants now, 14 under way, none of them phase 3. Uterine Cervical Dysplasia · United States.

Enrollment
26th of 86
201 · median 80
Started
2017
with 4 others
Phase 3
12 of 109
none open now
Registered
81st of 109
by date
Lead sponsor
3 of 109
Inovio Pharmaceuticals

Among the 109 studies in Uterine Cervical Dysplasia with a site in United States, this one is the 26th largest by enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2017, is one of 12 in phase 3, and was the 81st registered.

Uterine Cervical Dysplasia

409 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.

Browse Uterine Cervical Dysplasia studies →

Open to participants now

10 of the 109 studies in Uterine Cervical Dysplasia with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Uterine Cervical Dysplasia with a site in United States, or all of them as a file.
02

Study summary

HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) associated with human papillomavirus (HPV) 16 and/or HPV-18.

03

Conditions studied

  • Cervical Dysplasia
  • Cervical High Grade Squamous Intraepithelial Lesion
  • HSIL

Keywords

  • Cervical intraepithelial neoplasia (CIN)
  • Human papillomavirus (HPV)
  • High grade squamous intraepithelial lesion (HSIL)
  • CIN 2
  • CIN 3
  • papillomavirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 years and above
  • Confirmed cervical infection with HPV types 16 and/or 18 at screening
  • Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for diagnosis scheduled to be collected within 10 weeks prior to anticipated date of first dose of study drug
  • Confirmed histologic evidence of cervical HSIL at screening
  • Must be judged by Investigator to be an appropriate candidate for the protocol-specified procedure required at Week 36
  • With respect to their reproductive capacity must be or surgically sterile or willing to use a method with failure rate of less than 1% per year when used consistently and correctly from screening until Week 36
  • Normal screening (ECG)

Exclusion criteria

Exclusion Criteria:

  • Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar, vaginal, or anal intraepithelial neoplasia or invasive cancer in any histopathologic specimen at screening
  • Cervical lesion(s) that cannot be fully visualized on colposcopy
  • History of endocervical curettage (ECC) which showed cervical HSIL indeterminate, or insufficient for diagnosis
  • Treatment for cervical HSIL within 4 weeks prior to screening
  • Pregnant, breastfeeding or considering becoming pregnant during the study
  • History of previous therapeutic HPV vaccination
  • as a result of underlying illness or treatment
  • Receipt of any non-study, non- within 2 weeks of Day 0
  • Receipt of any non-study, live vaccine within 4 weeks of Day 0
  • Current or history of , medically unstable disease or condition which, in the judgment of the investigator, would jeopardize the safety of the participant, interfere with study assessments or endpoint evaluation, or otherwise impact the validity of the study results
  • Presence of acute or chronic bleeding or clotting disorder that would contraindicate IM injections, or use of blood thinners within 2 weeks of Day 0
  • Participation in an interventional study with an compound or device within 30 days of signing
  • Less than two acceptable sites available for IM injection
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    VGX-3100 + EP

    Participants received three IM injections of 6 milligram (mg) (in 1 milliliter \[mL\]) VGX-3100 followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.

    Biological: VGX-3100 · Device: Electroporation (EP)

  • Placebo comparator
    Placebo + EP

    Participants received three IM injections of 1 mL VGX-3100 matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.

    Biological: Placebo · Device: Electroporation (EP)

Interventions

  • BiologicalVGX-3100

    1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.

  • BiologicalPlacebo

    1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.

  • DeviceElectroporation (EP)

    Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples

    Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep®.

    Time frame: Week 36

Secondary outcomes

  1. Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. An SAE is any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.

    Time frame: From baseline up to Week 88

  2. Percentage of Participants With No Evidence of Cervical HSIL on Histology

    Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL.

    Time frame: Week 36

  3. Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing

    Participants with no evidence of HPV-16 and/or HPV-18 at the Week 36 time frame and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep®.

    Time frame: Week 36

  4. Percentage of Participants With No Evidence of LSIL or HSIL on Histology

    Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at the Week 36 time frame and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined as no evidence of cervical squamous intraepithelial neoplasia 1 (CIN1), CIN2, or CIN3 on biopsies or excisional treatment.

    Time frame: Week 36

  5. Percentage of Participants With No Evidence of LSIL or HSIL and No Evidence of HPV-16 and/or HPV-18

    Participants with no histologic evidence of cervical HSIL, squamous atypia, and LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at the Week 36 time, and participants in which an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment.

    Time frame: Week 36

  6. Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma

    Participants with no histologic evidence of cervical Adenocarcinoma in situ or cervical carcinoma at the Week 36 timeframe relative to baseline and participants in which an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered as responders.

    Time frame: Week 36

  7. Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations

    Participants with no evidence of HPV-16 and/or HPV-18 on specimens from noncervical anatomic locations (oropharynx, vagina and intra-anal) at the Week 36 time frame were considered as responder.

    Time frame: Week 36

  8. Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations

    A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100.

    Time frame: Week 15 and Week 36

  9. Change From Baseline in Interferon-Gamma Response Magnitude

    Assessment of cellular immune activity occurred via the application of the Interferon-γ enzyme-linked immunosorbent spot (IFN-γ ELISpot). Peripheral blood mononuclear cells (PBMCs) isolated from whole blood sample were used for analysis.

    Time frame: Baseline; Week 15 and Week 36

  10. Change From Baseline in Flow Cytometry Response Magnitude

    Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38 and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here change from baseline in CD8+CD137+Perforin+, CD8+CD38+Perforin+ and CD8+CD69+Perforin+ are reported.

    Time frame: Baseline, Week 15

07

Results

Posted Jul 25, 2023

Participant flow

Participants took part in the study at 96 study centers in 20 countries from 28 June 2017 to 6 April 2021.

Participant flow — Overall Study
MilestoneVGX-3100 + Electroporation (EP)Placebo + EP
Started13863
Intent-to-treat (itt) population13863
Modified itt (mitt) population13463
Safety population13663
Completed11656
Not completed227
Withdrew: Withdrawal by subject53
Withdrew: Adverse event10
Withdrew: Progressive disease10
Withdrew: Lost to follow-up82
Withdrew: Physician decision10
Withdrew: Protocol deviation20
Withdrew: Reason not specified32
Withdrew: Death10

Outcome measures

PrimaryPercentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples

Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep®.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples
percentage of participantsVGX-3100 + Electroporation (EP)Placebo + EP
Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples22.511.1
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Miettinen and Nurminen method · p = 0.029 · Difference in percentage: 11.4 · 95% CI -0.4 to 21.2
SecondaryNumber of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. An SAE is any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.

Time frame:
From baseline up to Week 88
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study
ParticipantsVGX-3100 + Electroporation (EP)Placebo + EP
Number of Participants with any AE13161
Number of Participants with any SAE136
SecondaryPercentage of Participants With No Evidence of Cervical HSIL on Histology

Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With No Evidence of Cervical HSIL on Histology
percentage of participantsVGX-3100 + Electroporation (EP)Placebo + EP
Percentage of Participants With No Evidence of Cervical HSIL on Histology31.919.0
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in percentage: 12.8 · 95% CI -0.6 to 24.5
SecondaryPercentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing

Participants with no evidence of HPV-16 and/or HPV-18 at the Week 36 time frame and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep®.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing
percentage of participantsVGX-3100 + Electroporation (EP)Placebo + EP
Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing34.115.9
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in percentage: 18.2 · 95% CI 5.1 to 29.4
SecondaryPercentage of Participants With No Evidence of LSIL or HSIL on Histology

Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at the Week 36 time frame and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined as no evidence of cervical squamous intraepithelial neoplasia 1 (CIN1), CIN2, or CIN3 on biopsies or excisional treatment.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With No Evidence of LSIL or HSIL on Histology
percentage of participantsVGX-3100 + Electroporation (EP)Placebo + EP
Percentage of Participants With No Evidence of LSIL or HSIL on Histology24.611.1
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in percentage: 13.5 · 95% CI 1.7 to 23.5
SecondaryPercentage of Participants With No Evidence of LSIL or HSIL and No Evidence of HPV-16 and/or HPV-18

Participants with no histologic evidence of cervical HSIL, squamous atypia, and LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at the Week 36 time, and participants in which an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With No Evidence of LSIL or HSIL and No Evidence of HPV-16 and/or HPV-18
percentage of participantsVGX-3100 + Electroporation (EP)Placebo + EP
Percentage of Participants With No Evidence of LSIL or HSIL and No Evidence of HPV-16 and/or HPV-1818.16.3
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in percentage: 11.8 · 95% CI 1.5 to 20.3
SecondaryPercentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma

Participants with no histologic evidence of cervical Adenocarcinoma in situ or cervical carcinoma at the Week 36 timeframe relative to baseline and participants in which an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered as responders.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma
percentage of participantsVGX-3100 + Electroporation (EP)Placebo + EP
Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma84.185.7
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in percentage: -1.7 · 95% CI -11.5 to 10.3
SecondaryPercentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations

Participants with no evidence of HPV-16 and/or HPV-18 on specimens from noncervical anatomic locations (oropharynx, vagina and intra-anal) at the Week 36 time frame were considered as responder.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations
percentage of participantsVGX-3100 + Electroporation (EP)Placebo + EP
Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations20.39.5
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in percentage: 10.8 · 95% CI -0.5 to 20.1
SecondaryLevels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations

A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100.

Time frame:
Week 15 and Week 36
Reported as:
Median · reciprocal endpoint titer
Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations
reciprocal endpoint titerVGX-3100 + Electroporation (EP)Placebo + EP
HPV-16 E7 at Week 15225.0 (1 to 18225)1.0 (1 to 6075)
HPV-16 E7 at Week 361.0 (1 to 18225)1.0 (1 to 6075)
HPV-18 E7 at Week 152025.0 (1 to 18225)1.0 (1 to 18225)
HPV-18 E7 at Week 36225.0 (1 to 18225)1.0 (1 to 2025)
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Location shift: 224.0 · 95% CI 24.0 to 224.0
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Location shift: 0.0 · 95% CI 0.0 to 0.0
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Location shift: 2024.0 · 95% CI 2000.0 to 6050.0
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Location shift: 224.0 · 95% CI 74.0 to 674.0
SecondaryChange From Baseline in Interferon-Gamma Response Magnitude

Assessment of cellular immune activity occurred via the application of the Interferon-γ enzyme-linked immunosorbent spot (IFN-γ ELISpot). Peripheral blood mononuclear cells (PBMCs) isolated from whole blood sample were used for analysis.

Time frame:
Baseline; Week 15 and Week 36
Reported as:
Median · spot forming units (SFU)/10^6 PBMC
Change From Baseline in Interferon-Gamma Response Magnitude
spot forming units (SFU)/10^6 PBMCVGX-3100 + Electroporation (EP)Placebo + EP
HPV-16 E6: Baseline0.83 (0.0 to 40.0)0.00 (0.0 to 16.7)
HPV-16 E6: Change from Baseline at Week 1513.33 (0.0 to 446.7)0.00 (0.0 to 13.3)
HPV-16 E6: Change from Baseline at Week 368.33 (0.0 to 780.0)0.00 (0.0 to 25.0)
HPV-16 E7: Baseline0.00 (0.0 to 53.3)0.00 (0.0 to 83.3)
HPV-16 E7: Change from Baseline at Week 1510.83 (0.0 to 213.3)0.00 (0.0 to 13.3)
HPV-16 E7: Change from Baseline at Week 367.50 (0.0 to 81.7)0.00 (0.0 to 8.3)
HPV-18 E6: Baseline0.00 (0.0 to 10.0)0.00 (0.0 to 20.0)
HPV-18 E6: Change from Baseline at Week 1550.83 (0.0 to 1910.0)0.00 (0.0 to 6.7)
HPV-18 E6: Change from Baseline at Week 3638.33 (0.0 to 1031.7)0.0 (0.0 to 23.3)
HPV-18 E7: Baseline0.00 (0.0 to 11.7)0.00 (0.0 to 91.7)
HPV-18 E7: Change from Baseline at Week 1514.17 (0.0 to 251.7)0.00 (0.0 to 20.0)
HPV-18 E7: Change from Baseline at Week 3610.00 (0.0 to 508.3)0.00 (0.0 to 6.7)
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Location shift: 11.67 · 95% CI 8.33 to 20.00
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 8.33 · 95% CI 3.33 to 11.67
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 10.83 · 95% CI 5.00 to 15.00
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 7.50 · 95% CI 1.67 to 10.00
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 50.83 · 95% CI 31.67 to 66.67
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 38.33 · 95% CI 18.33 to 51.67
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 14.17 · 95% CI 6.67 to 18.33
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 10.00 · 95% CI 5.00 to 15.00
SecondaryChange From Baseline in Flow Cytometry Response Magnitude

Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38 and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here change from baseline in CD8+CD137+Perforin+, CD8+CD38+Perforin+ and CD8+CD69+Perforin+ are reported.

Time frame:
Baseline, Week 15
Reported as:
Median · SFU/10^6 PBMC
Change From Baseline in Flow Cytometry Response Magnitude
SFU/10^6 PBMCVGX-3100 + Electroporation (EP)Placebo + EP
CD8+CD137+Perforin+: Baseline0.004 (0.00 to 0.15)0.001 (0.00 to 0.22)
CD8+CD137+Perforin+: Change from Baseline at Week 150.035 (0.00 to 0.44)0.000 (0.00 to 0.10)
CD8+CD38+Perforin+: Baseline0.000 (0.00 to 0.21)0.000 (0.00 to 0.12)
CD8+CD38+Perforin+: Change from Baseline at Week 150.011 (0.00 to 0.23)0.000 (0.00 to 0.10)
CD8+CD69+Perforin+: Baseline0.009 (0.00 to 0.11)0.001 (0.00 to 0.13)
CD8+CD69+Perforin+: Change from Baseline at Week 150.044 (0.00 to 0.37)0.000 (0.00 to 0.07)
Statistical analysis
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 0.025 · 95% CI 0.002 to 0.046
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 0.011 · 95% CI 0.000 to 0.014
  • VGX-3100 + Electroporation (EP) vs Placebo + EP · Difference in median: 0.044 · 95% CI 0.017 to 0.058

Adverse events

Collected over From baseline up to Week 88. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VGX-3100 + Electroporation (EP)1/136 (0.7%)13/136 (9.6%)131/136 (96.3%)
Placebo + EP0/62 (0%)6/62 (9.7%)61/62 (98.4%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventVGX-3100 + Electroporation (EP)Placebo + EP
Squamous Cell Carcinoma of the CervixNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/1360/62
Cervix CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1362/62
Adenosquamous Carcinoma of the CervixNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1361/62
Upper Limb FractureInjury, poisoning and procedural complications0/1361/62
Abortion SpontaneousPregnancy, puerperium and perinatal conditions0/1361/62
Ectopic PregnancyPregnancy, puerperium and perinatal conditions0/1361/62
Vaginal HaemorrhageReproductive system and breast disorders0/1361/62
Ligament InjuryInjury, poisoning and procedural complications1/1360/62
Diaphragmatic HerniaGastrointestinal disorders1/1360/62
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/1360/62
Most frequent other events
Showing 10 of 17
Most frequent other events
EventVGX-3100 + Electroporation (EP)Placebo + EP
Injection Site PainGeneral disorders105/13649/62
HeadacheNervous system disorders46/13619/62
FatigueGeneral disorders40/13618/62
Injection Site PruritusGeneral disorders34/13614/62
Injection Site ErythemaGeneral disorders33/13614/62
Injection Site SwellingGeneral disorders28/13615/62
MyalgiaMusculoskeletal and connective tissue disorders28/13614/62
NauseaGastrointestinal disorders25/13611/62
Injection Site BruisingGeneral disorders14/1369/62
Injection Site HaematomaGeneral disorders8/1366/62

Baseline characteristics

ITT population included all participants who were randomized.

Age, Continuous
Age, Continuous(years)VGX-3100 + Electroporation (EP)Placebo + EPTotal
Mean31.3 ± 6.5331.9 ± 6.0831.5 ± 6.38
Sex: Female, Male
Sex: Female, Male(Participants)VGX-3100 + Electroporation (EP)Placebo + EPTotal
Female13863201
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VGX-3100 + Electroporation (EP)Placebo + EPTotal
Hispanic or Latino22931
Not Hispanic or Latino11254166
Unknown or Not Reported404
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VGX-3100 + Electroporation (EP)Placebo + EPTotal
American Indian or Alaska Native011
Asian9615
Black or African American8513
Native Hawaiian or Other Pacific Islander011
White10946155
Other10212
Multiple101
Missing123
08

Study locations

60 sites
  • Mesa Obstetricians and Gynecologist
    Mesa, Arizona 85209, United States
  • Women's Health Research
    Scottsdale, Arizona 85251, United States
  • Visions Clinical Research-Tucson
    Tucson, Arizona 85712, United States
  • Women's Medical Research Group
    Clearwater, Florida 33759, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • Salom and Tangir LLC
    Miramar, Florida 33461, United States
  • Comprehensive Clinical Trials LLC
    West Palm Beach, Florida 33409, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Praetorian Pharmaceutical Research, LLC
    Marrero, Louisiana 70072, United States
  • Saginaw Valley Medical Research Group LLC
    Saginaw, Michigan 48604, United States
  • Meridian Clinical Research Norfolk
    Norfolk, Nebraska 68701, United States
  • New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Suffolk Obstetrics and Gynecology
    Port Jefferson, New York 11777, United States
  • Lyndhurst Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Greenville Pharmaceutical Research, Inc.
    Greenville, South Carolina 29615, United States
  • Magnolia Ob/Gyn Research Center, LLC
    Myrtle Beach, South Carolina 29572, United States
  • Chattanooga Medical Research Inc
    Chattanooga, Tennessee 37404, United States
  • Women's Physician Group
    Memphis, Tennessee 38104, United States
  • UAG Innovation Women Research, LLC
    Houston, Texas 77074, United States
  • Group For Women
    Norfolk, Virginia 23502, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
  • Instituto de Ginecología
    Rosario, Santa Fe S2000PBB, Argentina
  • Hospital Italiano de Buenos Aires
    Ciudad Autonoma de Buenos Aires, C1181ACH, Argentina
  • DIM Clínica Privada
    Ramos Mejía, B1704ETD, Argentina
  • Centre Hospitalier Universitaire Ambroise Paré
    Mons, Hainaut 7000, Belgium
  • Ziekenhuis Oost-Limburg
    Genk, Limburg 3600, Belgium
  • Pärnu Hospital
    Pärnu, Pärnumaa EE-80010, Estonia
  • East Tallinn Central Hospital Womens Clinic
    Tallin, 10119, Estonia
  • Tartu University Hospital
    Tartu, 51014, Estonia
  • Kätilöopiston sairaala
    Helsinki, 290, Finland
  • Lääkäriasema Cantti Oy
    Kuopio, FI-70110, Finland
  • Elisabeth Krankenhaus Essen GmbH
    Essen, 45138, Germany
  • Universitätsklinikum Hamburg Eppendorf
    Hamburg, 20246, Germany
  • Fondazione Policlinico Universitario A Gemelli
    Roma, Lazio 00168, Italy
  • Istituto Nazionale Dei Tumori
    Milano, 20133, Italy
  • Istituto Europeo Di Oncologia
    Milan, 20141, Italy
  • Vilnius University Hospital Santaros Klinikos
    Vilnius, LT- 08661, Lithuania
  • Vilnius District Central Outpatient Clinic
    Vilnius, LT-01117, Lithuania
  • Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca
    Guadalajara, Jalisco 44340, Mexico
  • Unidad de Ensayos Clinicos (UNIDEC) del Policlinico Universidad Nacional Mayor de San Marcos
    Lima, 15083, Peru
  • Liga Peruana De Lucha Contra El Cancer
    Lima, 15084, Peru
  • Perpetual Succour Hospital
    Cebu, 6000, Philippines
  • Niepubliczny Zakład Opieki Zdrowotnej Profimed
    Lublin, Lubelskie 20-880, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie
    Lublin, Lubelskie 20-880, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Centro Hospitalar E Universitário de Coimbra EPE
    Coimbra, 3000-075, Portugal
  • Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
    Lisboa, 1649-035, Portugal
  • Puerto Rico Translational Research Center (PRTRC)
    Rio Piedras, 00935, Puerto Rico
  • MCM GYNPED, s.r.o.
    Dubnica Nad Váhom, 018 41, Slovakia
  • Univerzitna nemocnica Martin
    Martin, 036 59, Slovakia
  • Lynette Reynders Private Practice
    Centurion, Gauteng 157, South Africa
  • University of Cape Town
    Cape Town, 7925, South Africa
  • Hospital Universitario de Bellvitge
    Hospitalet de Llobregat, Barcelona 8907, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Chulalongkorn University
    Bangkok, 10700, Thailand
  • Siriraj Hospital Mahidol University
    Bangkok, 10700, Thailand
  • Aberdeen Royal Infirmary - PPDS
    Aberdeen, AB25 7ZD, United Kingdom
  • St Marys Hospital
    London, W2 1NY, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Jul 2020, 36 months.

Results were first posted in Jul 2023, 3 years after primary completion. A results delay was requested in Jul 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2017
First posted
Jun 14, 2017
StartActual
Jun 28, 2017
Primary completionActual
Jul 8, 2020
CompletionActual
Apr 6, 2021
Results delay requested
Jul 1, 2021
Results first posted
Jul 25, 2023
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03185013
Responsible party
Sponsor
First posted
Jun 14, 2017
Start date
Jun 28, 2017
Primary completion
Jul 8, 2020
Completion
Apr 6, 2021
Results posted
Jul 25, 2023
Last update
Jul 27, 2023

Study contacts

Jeffrey Skolnik, MD
study director · Inovio Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VGX-3100

Start the discussion